The utilization of 3D organoids is increasingly prevalent in disease modeling and drug discovery due to their ability to better represent biologically relevant tissue architecture, microenvironments, and functionality. However, the complex nature of 3D models is a potential obstacle to their greater utilization in drug screening and research.
Molecular Devices LLC aims to overcome these obstacles by applying automation to labor-intensive manual protocols. As a result, the company has established automation protocols for the entire 3D culture workflow process and increased organoid assays’ accuracy and throughput.
These automated methods employ an integrated work cell, facilitating automated cell plating, media exchange, […]
Full Post at www.news-medical.net